Optinose to Highlight Data at Two Upcoming Scientific Meetings

World News: . []

YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data concerning its product XHANCE® will be presented at the American Rhinologic Society (ARS) 64 Annual Meeting in Atlanta, Georgia, October 5-6, 2018, and the American Academy Of Otolaryngology-Head and Neck Surgery Annual Meeting in Atlanta, Georgia, October 7-10, 2018. Abstracts are available on the ARS Annual Meeting and AAO-HNSF Annual Meeting websites. XHANCE® (fluticasone propionate) nasal spray, 93 mcg, is approved by the U.S. Food and Drug Administration for the treatment of nasal polyps in patients 18 years of age or older. 

Data on XHANCE, also referred to as the Exhalation Delivery System with fluticasone (EDS-FLU), is expected to be highlighted in three podium presentations and one scientific poster presented during the ARS Annual Meeting:

XHANCE data is expected to be highlighted in one podium presentation during the AAO-HNSF Annual Meeting:

These presentations are intended for scientific discussion only.

Please see the full Prescribing Information at .

More news and information about OptiNose, Inc.

Published By:

Globe Newswire: 12:00 GMT Wednesday 3rd October 2018

Published: .

Search for other references to "optinose" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us